Safety and immunogenicity of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine (TetraMen-T) in toddlers.

Trial Profile

Safety and immunogenicity of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine (TetraMen-T) in toddlers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2013

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Nov 2011 Results published in the Pediatric Infectious Disease Journal.
    • 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top